New bladder cancer research may improve survival rates and reduce the chances of recurrence.
Recent advances in the treatment of bladder cancer have introduced promising new strategies that could improve outcomes for patients, including those with advanced and high-risk forms of the disease. The potential for a cure has grown with the incorporation of immune therapies and more accurate patient selection methods, which brings hope to many patients and their families.
Bladder cancer treatment has traditionally been based on chemotherapy, particularly platinum-based drugs, which are used both for advanced cases and in neoadjuvant settings prior to surgery for muscle-invasive bladder cancer. While these treatments have provided some success, recent breakthroughs suggest that combining chemotherapy with other treatments could produce even better results.
Specifically, immune checkpoint inhibitors, which work by enhancing the body’s immune system to target cancer cells, have become a central part of new treatment protocols. These drugs effectively “release the brakes” on immune cells, allowing them to recognize and attack the tumor. When combined with chemotherapy, or more advanced therapies such as antibody-drug conjugates like enfortumab vedotin (approved by the FDA in 2019), the treatments have shown much greater effectiveness than chemotherapy on its own.
The introduction of combination therapies has led to promising early-stage trials, including the NIAGARA trial, which evaluated the impact of combining the immune checkpoint inhibitor durvalumab with chemotherapy before and after bladder removal surgery. This study demonstrated that patients who received this combination therapy had a much higher survival rate over two years compared to those who were treated with chemotherapy alone. Additionally, these patients were less likely to experience cancer recurrence and had better disease progression-free survival rates.
While the NIAGARA trial is game-changing, it also raised important questions about the best approach to treatment. One key limitation of the study is that it did not fully isolate the effects of the pre- and post-surgery phases of treatment, making it difficult to pinpoint which part of the therapy provided the greatest benefit. As a result, researchers pointed out the need for future trials that address this gap, ensuring that additional treatments do not lead to unnecessary side effects or reduced quality of life.
The next phase of bladder cancer treatment lies in the use of predictive biomarkers. These tools can help identify which patients are most at risk of having cancer recur and guide more personalized treatment plans. One exciting development is the use of circulating tumor DNA, which can provide valuable insights into the likelihood of a patient’s cancer returning. This approach could help doctors decide which patients would benefit most from additional therapies while avoiding overtreatment in those who may not need it. By identifying the right patients for the right treatment, doctors can minimize side effects and maximize therapeutic outcomes.
Looking ahead, advances in bladder cancer treatment are expected to become more targeted and effective, with the promise of improving survival rates and reducing the chances of recurrence. With ongoing research into predictive biomarkers and the continued development of immune therapies, it is likely that more patients will experience better outcomes, ultimately leading to fewer lives lost to this aggressive cancer.
Sources:
Advances in bladder cancer treatments offer hope for curative care
Toward Curing More Patients with Bladder Cancer — A New Perioperative Strategy
Join the conversation!